Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6

Benzinga Newsdesk www.benzinga.com Positive 54.5%

Neg 0% Neu 0% Pos 54.5%

Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $6.